Loading the section…
The price of Stoke Therapeutics, Inc. (STOK) on October 9, 2026 is 24.74 USD, +3.30% on the day. Over 52 weeks the stock traded between 20.32 USD and 40.22 USD; the price now sits 22% of the way up that range. Over the past year the price changed by -18.89%. Market capitalization is 1.54 billion USD, rank 93 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): −18.46 %
Stoke Therapeutics, Inc. trades on Nasdaq under the ticker STOK. The company belongs to the Health care sector. The trading history on this page starts on 19 June 2019.
Over the past 52 weeks STOK has traded between 20.32 $ and 40.22 $. As of 9 October 2026 the price stood 22.21 % of the way from the 52-week low to the high.
Over one year STOK shares fell 18.89 %; over six months they fell 27.93 %. Volatility over 90 days is 43.84 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 48.0, above the sector median of 4.0. Price to book is 3.9, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 23.98 | 25.20 | 23.79 | 24.74 | 919,000 |
| 8 October 2026 | 24.04 | 24.29 | 23.65 | 23.95 | 692,300 |
| 7 October 2026 | 24.13 | 24.70 | 23.95 | 24.29 | 637,100 |
| 6 October 2026 | 25.58 | 25.73 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Stoke Therapeutics, Inc. (STOK) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 32.1m $, net income was -169.8m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:45 WIGGINS AVENUE, BEDFORD, MA, 01730, US
Stoke Therapeutics, Inc. reported revenue of 32M $ and a net loss of 170M $ over the last four quarters. Net margin is −529.20 %. Revenue changed by −83.20 % year over year. Earnings per share are −2.81 $. Market capitalisation is 1.5B $.
STOK has a return on equity of −42.99 %, below the sector median of −41.68 %. Return on assets is −38.30 %, below the sector median of −32.11 %. Operating margin is −577.46 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 23.00 |
| 24.37 |
| 1M |
| 5 October 2026 | 25.82 | 26.31 | 24.84 | 25.32 | 928,400 |
| 2 October 2026 | 26.46 | 26.46 | 25.45 | 25.62 | 848,600 |
| 1 October 2026 | 26.06 | 26.51 | 25.91 | 26.01 | 1M |
| 30 September 2026 | 26.12 | 26.69 | 25.88 | 26.00 | 2M |
| 29 September 2026 | 25.31 | 25.99 | 25.12 | 25.88 | 1M |
| 28 September 2026 | 24.51 | 25.71 | 24.21 | 25.50 | 2M |
| 25 September 2026 | 25.47 | 25.52 | 24.80 | 24.80 | 1M |
| 24 September 2026 | 26.09 | 26.30 | 25.00 | 25.29 | 1M |
| 23 September 2026 | 29.22 | 29.22 | 26.02 | 26.11 | 1M |
| 22 September 2026 | 28.44 | 29.40 | 28.24 | 29.20 | 527,200 |
| 21 September 2026 | 28.80 | 28.80 | 27.75 | 28.05 | 720,000 |
| 18 September 2026 | 28.85 | 28.91 | 28.01 | 28.43 | 2M |
| 17 September 2026 | 28.41 | 29.13 | 28.36 | 28.93 | 960,100 |
| 16 September 2026 | 28.25 | 28.60 | 27.66 | 27.91 | 592,000 |
| 15 September 2026 | 29.56 | 29.56 | 27.82 | 28.15 | 1M |
| 14 September 2026 | 29.38 | 29.70 | 29.01 | 29.60 | 500,400 |